Kula Investments’s Amylyx Pharmaceuticals AMLX Stock Holding History

Kula Investments’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$367K	Buy	+12,507	New	+$434K	0.09%	396

Other funds holding AMLX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Kula Investments's AMLX Position: Q1 2023 in Review

Kula Investments opened a new position in Amylyx Pharmaceuticals (AMLX) in Q1 2023: 12,507 shares worth $367K. The stake represents 0.09% of the portfolio and ranks #396 among its holdings.

147 funds tracked by Wall St. Rank hold AMLX as of Q1 2023.

Kula Investments held 12,507 shares of Amylyx Pharmaceuticals worth $367K as of Q1 2023.
Amylyx Pharmaceuticals was a new Kula Investments position in Q1 2023.
Amylyx Pharmaceuticals made up 0.09% of Kula Investments's portfolio in Q1 2023, its #396 holding.
147 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2023.

Based on Kula Investments's 13F filing for Q1 2023, filed 15 May 2023.